Skip to main content
. Author manuscript; available in PMC: 2022 Jul 1.
Published in final edited form as: Cancer Lett. 2021 Apr 1;509:1–12. doi: 10.1016/j.canlet.2021.03.026

Figure 4.

Figure 4.

Benefits of PPI usage and differential effects of R- and S-enantiomers. A–C, Kaplan-Meier analysis of PPI usage on overall survival of all (A) or Caucasian American (B) and African American (C) breast cancer patients. D, User distribution of different PPIs. The other PPI user group includes dexlansoprazole and rabeprazole single users. E, Kaplan-Meier analysis of overall survival analysis of breast cancer patients using single and multiple PPIs. F, Inhibition of TE activity of FASN by R and S enantiomers of omeprazole and lansoprazole. Censored data are shown by diamonds.